Industry Experts

Sriram, a seasoned biotechnology executive with over two decades of experience in drug development, is a perpetual student of immunology. He has made significant contributions to the development of novel immunotherapeutics, some of which have received regulatory approval, while others are in clinical trials. Before joining Foundery Biosciences, Sriram was an early employee at Pionyr Immunotherapeutics, where he built the research team, led the operational move to an independent facility, and served as the nonclinical lead for the PY314 (anti-TREM2) program. Before Pionyr, Sriram worked at Gilead Sciences and Merck, where he established and led several immuno-oncology programs. At Merck Research Laboratories, Sriram also served as the cross-site pharmacology lead for immuno-oncology programs, including the anti-PD-1 antibody, Keytruda. Sriram received his Ph.D. in Biochemistry and Immunology from the University of Madras, India, and completed his post-doctoral training in immunology at the Indiana University School of Medicine.